

## Correction

### Prescribing for transgender patients [Correction]

*Aust Prescr* 2019;42:145

<https://doi.org/10.18773/austprescr.2019.053>

First published 4 July 2019

The article on prescribing for transgender patients ([Aust Prescr 2019;42:10-3](#)) has been corrected.

In the second paragraph of the 'Monitoring' section, the target estradiol level for transwomen on treatment should be 400–700 pmol/L (not 400–700 mmol/L).

## EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

*Postal* The Editor  
*Australian Prescriber*  
 Level 5, 15 Moore Street  
 Canberra, ACT 2600

*Telephone* +61 2 8217 8700

*Email* [info@australianprescriber.com](mailto:info@australianprescriber.com)

*Website* [nps.org.au/australian-prescriber](http://nps.org.au/australian-prescriber)

*Twitter* @AustPrescriber

## SUBSCRIPTIONS

*Australian Prescriber* is published every two months online. All content is accessible free of charge in full text at [nps.org.au/australian-prescriber](http://nps.org.au/australian-prescriber). New drugs are published between issues as they become available.

**An email alert** can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at [nps.org.au/australian-prescriber](http://nps.org.au/australian-prescriber)

For free copies of the Anaphylaxis wallchart and Switching-antidepressants poster, order online at [www.nps.org.au/order#for-health-professionals](http://www.nps.org.au/order#for-health-professionals)

© 2019 NPS MedicineWise  
 ABN 61 082 034 393

### NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.